VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

BSH 2021 | Venetoclax and azacitidine in older patients with AML

Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, discusses the use of venetoclax and azacitidine in older adults with acute myeloid leukemia (AML). Combining venetoclax and azacytidine resulted in a median survival rate of 14.7 months, a significant improvement to azacitidine monotherapy. Prof. Vyas also hopes this treatment regimen, which has already been approved in the US, will establish improved treatments for certain genetic subgroups. This interview took place at the 2021 British Society for Haematology Annual Scientific Meeting.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter